MA52370B1 - Pyridine derivatives and their therapeutic uses as trpc6 inhibitors - Google Patents

Pyridine derivatives and their therapeutic uses as trpc6 inhibitors

Info

Publication number
MA52370B1
MA52370B1 MA52370A MA52370A MA52370B1 MA 52370 B1 MA52370 B1 MA 52370B1 MA 52370 A MA52370 A MA 52370A MA 52370 A MA52370 A MA 52370A MA 52370 B1 MA52370 B1 MA 52370B1
Authority
MA
Morocco
Prior art keywords
therapeutic uses
compounds
pyridine derivatives
trpc6
inhibitors
Prior art date
Application number
MA52370A
Other languages
French (fr)
Other versions
MA52370A (en
Inventor
Thierry Bouyssou
Dirk Gottschling
Niklas Heine
Keenan Lana Louise Smith
Michael D Lowe
Hossein Razavi
Christopher Ronald Sarko
Simon Surprenant
Hidenori Takahashi
Michael Robert Turner
Xinyuan Wu
Original Assignee
Boehringer Ingelheim Int
Hydra Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Hydra Biosciences Llc filed Critical Boehringer Ingelheim Int
Priority claimed from PCT/EP2018/079276 external-priority patent/WO2019081637A1/en
Publication of MA52370A publication Critical patent/MA52370A/en
Publication of MA52370B1 publication Critical patent/MA52370B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

L'invention concerne de nouveaux composés ayant une activité inhibitrice de trpc6 et leurs sels pharmaceutiquement acceptables. L'invention concerne également des compositions pharmaceutiques comprenant ces composés, l'utilisation de ces composés dans le traitement de diverses maladies et troubles, des procédés de préparation de ces composés et des intermédiaires utiles dans ces procédés.The invention relates to novel compounds having trpc6 inhibitory activity and their pharmaceutically acceptable salts. The invention also relates to pharmaceutical compositions comprising these compounds, the use of these compounds in the treatment of various diseases and disorders, processes for the preparation of these compounds and intermediates useful in these processes.

MA52370A 2017-10-27 2018-10-25 Pyridine derivatives and their therapeutic uses as trpc6 inhibitors MA52370B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577883P 2017-10-27 2017-10-27
PCT/EP2018/079276 WO2019081637A1 (en) 2017-10-27 2018-10-25 Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors

Publications (2)

Publication Number Publication Date
MA52370A MA52370A (en) 2022-03-30
MA52370B1 true MA52370B1 (en) 2022-12-30

Family

ID=71523229

Family Applications (2)

Application Number Title Priority Date Filing Date
MA50457A MA50457B1 (en) 2017-10-27 2018-10-25 PYRIDINE CARBONYL DERIVATIVES AND THEIR THERAPEUTIC USES AS TRPC6 INHIBITORS
MA52370A MA52370B1 (en) 2017-10-27 2018-10-25 Pyridine derivatives and their therapeutic uses as trpc6 inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA50457A MA50457B1 (en) 2017-10-27 2018-10-25 PYRIDINE CARBONYL DERIVATIVES AND THEIR THERAPEUTIC USES AS TRPC6 INHIBITORS

Country Status (2)

Country Link
AR (1) AR113794A1 (en)
MA (2) MA50457B1 (en)

Also Published As

Publication number Publication date
MA50457A (en) 2020-09-02
MA52370A (en) 2022-03-30
AR113794A1 (en) 2020-06-10
MA50457B1 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
MA43979B1 (en) 1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders
MA47079A (en) AMINO-TRIAZOLOPYIDINE COMPOUNDS AND THEIR USE TO TREAT CANCER
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
MA38380A1 (en) Quinazoline inhibitors of activation of mutant forms of epidermal growth receptor (EGFR)
MA40111B1 (en) Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein
MA34655B1 (en) AMINOALCOOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLEIN DERIVATIVES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND ANGIOGENESIS RELATED DISEASES
MA34474B1 (en) AGONISTS OF GPR40
MA44674A (en) BROMODOMAIN INHIBITORS
MA37762A1 (en) N-aryltriazole compounds used as antagonists of lpar
MA37764A1 (en) N-alkyltriazole compounds used as antagonists of lpar
MA33119B1 (en) BENZOFURANYL DERIVATIVES AS GLUCOKINASE INHIBITORS
MA38648B1 (en) Carboxamide compounds of substituted carbazole and tetrahydrocarbazole suitable as kinase inhibitors
BR112014006763A2 (en) n- (3- (2-amino-6,6-difluoro-4,4a, 5,6,7,7a-hexahydro-cyclopenta [e] [1,3] oxazin-4-yl) -phenyl) -amides as bace1 inhibitors
MA37891B1 (en) Alcoxypyrazoles as activators of soluble guanylate cyclase
MA43052B1 (en) Human Plasma Kallikrein Inhibitors
MA37691A1 (en) 5-amino [1,4] thiazines as bace1 inhibitors
MA46229A (en) HETERARYL CARBOXAMIDE COMPOUNDS AS RIPK2 INHIBITORS
MA37763B1 (en) Difluoro-hexahydro-cyclopentaoxazinyl and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MA37765A1 (en) Substituted pyrazole compounds used as lpar antagonists
ATE444069T1 (en) QUINOLINE DERIVATIVES FOR THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISEASES
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
MA39229A1 (en) Pyrrolidines, terrahydrofurans and substituted cyclopentanes useful as orexin receptor antagonists
MA52370B1 (en) Pyridine derivatives and their therapeutic uses as trpc6 inhibitors
MA53372B1 (en) Pyridopyrimidinenes as histamine h4 receptor inhibitors
TN2014000371A1 (en) MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES